Antitumor effects of new-type recombinant interleukin-2.
Two new human recombinant interleukin-2 (rIL-2), 125-Ser-rIL-2, and 125-Ala-rIL-2, were generated by protein engineering technique. Both of them maintained the proliferation of natural killer (NK) cells, CTLL-2 cells and their long-term propagations. The mutated new rIL-2 also enhanced the bioactivity of NK cells and the cytotoxicity of tumor-infiltrating lymphocytes (TIL) against the target tumor cells. The above results were all compared with that of the native rIL-2 and a similarity between them was found, which indicates that new type rIL-2 could be used for adoptive immunotherapy of malignant diseases.
Feng
X S
XS
Department of Immunology, Shanghai Medical University, China.
Zheng
X J
XJ
Si
Q S
QS
Lin
Y L
YL
Chang
Y
Y
Fan
P F
PF
Yu
J L
JL
Zhang
S R
SR
Liu
X Y
XY
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000502:physiology*; D016246:Lymphocytes, Tumor-Infiltrating / Q000502:physiology*; D051379:Mice; D008809:Mice, Inbred C3H; D011994:Recombinant Proteins / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D007376:Interleukin-2; D011994:Recombinant Proteins